British pharmaceutical giant GSK and biotechnology innovator Moderna have officially resolved their high-stakes intellectual property dispute. The companies announced that they have settled lingering lawsuits which accused Moderna’s prominent COVID-19 vaccines, Spikevax and mNEXSPIKE, alongside its respiratory syncytial virus (RSV) shot mResvia, of infringing upon foundational GSK patents. The agreement, which brings an end to […]